background : the development of chemoresistance represents a major obstacle in the successful treatment of cancers such as non-hodgkin’s lymphoma (nhl). with the recognition of important roles for both p53 and its more recently described paralog p73 in mediating the activity of anti-cancer drugs, there has been increasing recognition that cellular resistance to anthracyclines could and does a...

Purpose: Individually targeting B-cell antigens with monoclonal antibody therapeutics has improved the treatment of non-Hodgkin lymphoma (NHL). We examined if the antitumor activity of rituximab, CD20-specific antibody, could be improved by simultaneously targeting CD40 with the humanized monoclonal antibody dacetuzumab (SGN-40). Experimental Design: Dacetuzumab was dosed with rituximab to dete...

PURPOSE Individually targeting B-cell antigens with monoclonal antibody therapeutics has improved the treatment of non-Hodgkin lymphoma (NHL). We examined if the antitumor activity of rituximab, CD20-specific antibody, could be improved by simultaneously targeting CD40 with the humanized monoclonal antibody dacetuzumab (SGN-40). EXPERIMENTAL DESIGN Dacetuzumab was dosed with rituximab to dete...

BACKGROUND The expression of chemokine receptors CCR7 has been studied in relation to tumor dissemination and poor prognosis in a limited number of cancers. No such studies have been done on CCR7 expression in non-Hodgkin's lymphoma (T-NHL). Our aim in this paper is to investigate the association between CCR7 expression and progression and prognosis of T-NHL. METHODS 1) Analysis of clinical d...

Calpain is a calcium-dependent cysteine protease that is implicated in calcium-dependent cell death, and calpain inhibitors are generally considered as inhibitors of apoptosis. To the contrary, in the present study, we found that calpain inhibitor II (CPI-2) triggers rapid apoptosis in acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL) cells. All target cell lines were killed b...

Treatment for childhood and adolescent non-Hodgkin lymphoma (NHL) has been optimised within the major biological subgroups for the last 30 years. Event-free survival rates reach almost 90% for mature B-cell NHL (B-NHL), 80% for lymphoblastic lymphomas (LBL) and 70% for anaplastic large cell lymphomas (ALCL). The efficacy of the front-line treatment leaves highly refractory relapsed disease, and...

Follicular lymphoma and diffuse large B cell lymphomas comprise the main entities of adult B cell malignancies. Although multiple disease driving gene aberrations have been identified by gene expression and genomic studies, only a few studies focused at the protein level. We applied 2 dimensional gel electrophoresis to compare seven GC B cell non Hodgkin lymphoma (NHL) cell lines with a lymphob...

BACKGROUND Primary refractory disease is a main challenge in the management of non-Hodgkin's Lymphoma (NHL). This survey was performed to define the rate of refractory disease to first-line therapy in B and T-cell NHL subtypes and the long-term survival of primary refractory compared to primary responsive patients. METHODS Medical records were reviewed of 3,106 patients who had undergone prim...

Lymphomas are classified as Hodgkin’s and Non-Hodgkin’s lymphomas (HL NHL) NHL being further sub-divided into B, T and Null cell categories on the basis of WHO classification. With a few exceptions worldwide, B-NHL are more common, accounting approximately 80-85% of all cases of NHL compared to T-NHL, which accounts for about 10-15% of all NHL cases. The incidence of NHL has shown a steady incr...

Background: To describe the treatment patterns, patient characteristics and usage pattern of biosimilar rituximab for Non-Hodgkin lymphomas (NHL) in India.Methods: This real-world, retrospective, analysis included adult patients receiving between April 2021 March 2022.Results: A total 750 with NHL who received were included. The most common indications reported this diffuse large cell B-cell ly...